23/11/2022 - 14:47

New trial data encourages Radiopharm on cancer tracer

23/11/2022 - 14:47


Save articles for future reference.

Medical technology company Radiopharm Theranostics says new data released by Imperial College London from a phase 2 trial it conducted on the company’s F-18 Pivalate radiotracer adds weight to its belief the product can be used to monitor brain cancer – a potentially huge market because up to 40 per cent of cancer patients develop metastatic cancer in the brain.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options